Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 5/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | TNKS | O95271 | 2/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29700725 | 1.00 | KRAS (0.38) | KRASTRPV1MAPK13MAPK12MAPK11 | |
| SCHEMBL21543288 | 0.90 | MAPK13 (0.38) | KRASTRPV1MAPK13MAPK12MAPK11 | |
| SCHEMBL30762794 | 0.90 | MAPK13 (0.38) | KRASTRPV1MAPK13MAPK12MAPK11 | |
| SCHEMBL29700616 | 0.90 | MAPK13 (0.42) | MAPK13MAPK12MAPK11MAPK14LMNA | |
| SCHEMBL24474404 | 0.90 | MAPK13 (0.42) | MAPK13MAPK12MAPK11MAPK14LMNA | |
| SCHEMBL20560733 | 0.89 | MAPK13 (0.39) | KRASTRPV1MAPK13MAPK12MAPK11 | |
| SCHEMBL30762757 | 0.89 | MAPK13 (0.39) | KRASTRPV1MAPK13MAPK12MAPK11 | |
| SCHEMBL23408978 | 0.85 | KRAS (0.37) | KRASTRPV1 | |
| SCHEMBL24474374 | 0.85 | MAPK13 (0.38) | KRASMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL23460335 | 0.84 | NLRP3 (0.35) | TRPV1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| EP-4101852-A1 | PYRIDOPYRIMIDINONE COMPOUND AND APPLICATION THEREOF | Bebetter Med Inc. (CN) | 2022-12-14 | — | — | EP | disclosed |
| US-20220389013-A1 | PYRIDOPYRIMIDINONE COMPOUNDS AND APPLICATIONS THEREOF | BEBETTER MED INC. (CN) | 2022-12-08 | — | — | US | disclosed |
| WO-2022111521-A1 | AROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州多域生物技术有限公司 | 2022-06-02 | — | — | WO | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3788038-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389013-A1 | PYRIDOPYRIMIDINONE COMPOUNDS AND APPLICATIONS THEREOF | KRAS, NRAS, HRAS | KRAS 1/4885TRPV1 4134/4885MAPK13 143/4885 |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KRAS 1/4885TRPV1 4825/4885MAPK13 962/4885 |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | KRAS 1/4885TRPV1 4825/4885MAPK13 962/4885 |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KRAS 1/4885TRPV1 4825/4885MAPK13 962/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KRAS 1/4885TRPV1 4825/4885MAPK13 962/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | KRAS 1/4885TRPV1 4825/4885MAPK13 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.